Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of adagrasib versus docetaxel in previously treated KRAS G12C-mutated non-small cell lung cancer
NL-OMON56384Phase 3Recruiting
- Sponsor
- Mirati Therapeutics
- Start
- Apr 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Adagrasib with Docetaxel (2 arms). Primary endpoint: Progression-free survival. Started Apr 2023; status: recruiting.
02
Drugs
adagrasibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON56384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56384.